Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene

[1]  H. Tsuda,et al.  PIK3CA mutation is an early event in the development of endometriosis‐associated ovarian clear cell adenocarcinoma , 2011, The Journal of pathology.

[2]  N. Ueno,et al.  Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. , 2011, Gynecologic oncology.

[3]  D. Holmes.  PI3K pathway inhibitors approach junction , 2011, Nature Reviews Drug Discovery.

[4]  A. Mes-Masson,et al.  Subtype‐specific mutation of PPP2R1A in endometrial and ovarian carcinomas , 2011, The Journal of pathology.

[5]  V. Velculescu,et al.  Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. , 2011, The American journal of pathology.

[6]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[7]  H. Itamochi.  Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. , 2010, World journal of biological chemistry.

[8]  R. Bernards,et al.  Inhibition of the PI3K Pathway: Hope We Can Believe in? , 2010, Clinical Cancer Research.

[9]  J. Engelman,et al.  The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[11]  J. Kigawa,et al.  Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma , 2008, Cancer science.

[12]  J. Kigawa,et al.  Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging , 2006, British Journal of Cancer.

[13]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[14]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[15]  Wei Zhao,et al.  Mutations of PIK3CA in gastric adenocarcinoma , 2005, BMC Cancer.

[16]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[17]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[18]  Mitsuaki Suzuki,et al.  Low Proliferation Activity May Be Associated With Chemoresistance in Clear Cell Carcinoma of the Ovary , 2002, Obstetrics and gynecology.

[19]  Mitsuaki Suzuki,et al.  Mechanisms of Cisplatin Resistance in Clear Cell Carcinoma of the Ovary , 2002, Oncology.

[20]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[21]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[22]  B. Vanhaesebroeck,et al.  The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.

[23]  B. Chauffert,et al.  Confluence‐dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells , 1992, International journal of cancer.

[24]  M. Barcellos-Hoff,et al.  Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells. , 1990, Cancer research.

[25]  Scully Re,et al.  World Health Organization classification and nomenclature of ovarian cancer. , 1975, National Cancer Institute monograph.

[26]  R. Scully.  World Health Organization classification and nomenclature of ovarian cancer. , 1975, National Cancer Institute monograph.

[27]  P. Kolstad,et al.  Mesonephroid Tumors of the Ovary: Clinical and Histopathologic Studies , 1971, Obstetrics and gynecology.